Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue

This image opens in the lightbox

News provided by

Daewoong Pharmaceutical Co., Ltd.

15 Nov, 2022, 10:18 GMT

Share this article

Share toX

Share this article

Share toX

  • Nabota exports grew significantly, achieving a 93.3% growth YOY, and overall revenue tops KRW 40.4 billion
  • Fexuclue, a new drug released last July, shows steep growth in market share in Korea
  • Nabota enters the European market and Fexuclue enters wide use as in prescriptions for gastritis indications, leading to expectations of continued strong sales

SEOUL, South Korea, Nov. 15, 2022 /PRNewswire/ -- Daewoong Pharmaceutical Co., Ltd. (CEO Jeon Sengho, Lee Changjae) announced the third-quarter financial results. Standalone revenue for the third quarter stood at KRW 301.5 billion while operating profit recorded KRW 30.3 billion, representing a year-over-year (YOY) increase of 13.7% and 26.7% respectively, while consolidated revenue stood at KRW 331.9 billion with operating profit of KRW 30.1 billion.

Continue Reading
This image opens in the lightbox
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue.

Daewoong Pharmaceutical (hereinafter, Daewoong) has exceeded KRW 300 billion in quarterly revenue for the first time, thanks to the strong export performance of the botulinum toxin Nabota, favorable exchange rates, and the growth of high-value products including Fexuclue, which was released last July.

Of especial note is Nabota, a botulinum toxin product which has seen a 93.3% growth in revenue YOY, achieving KRW 40.4 billion in sales. Of this figure, exports accounted for KRW 32.6 billion, a 130.2% increase from KRW 14.2 billion in the same period last year. Daewoong established a foothold in Europe, the second largest pharmaceutical market in the world with the release of Nabota in the UK last September. The company is expanding its market share through active marketing in the United States, the largest market. With the more natural treatment results of high-purity toxin products becoming increasingly known, sales have also increased in Southeast Asia and Central and South America, regions with sizeable markets for aesthetic plastic surgery.

With a presence already in the UK, Daewoong plans to enter valuable European markets, including Germany and Austria, within the year, while reinforcing marketing and training efforts targeted toward overseas medical professionals for the post-COVID era, in an effort to increase and develop sales and distribution channels overseas.

As for ethical drugs (ETC), sales recorded KRW 209.5 billion, a 6.5% increase from KRW 196.7 billion in the same quarter last year. Fexuclue, a treatment for gastroesophageal reflux disease (GERD), was made available for inclusion in healthcare benefits last July, after which it saw a rapid growth in market share and an increase in outside pharmacy prescriptions, as well as the establishment of a stable presence in major university and general hospitals and local markets. Furthermore, high-profitability products including hyperlipidemia treatments Crezet and Litorvazet, GERD treatment Nexierd, and Axid, an anti-ulcer product, have also contributed to the growth in the item category.

With clinically proven efficacy and safety, Fexuclue enjoys a strong prospect of increased acceptance and use among primary general hospitals, especially now it has acquired additional treatable indications for acute gastritis and gastric mucosa lesions associated with chronic gastritis, which are found commonly among Korean patients. Both the visibility and sales of the product are anticipated to grow considerably once actual prescriptions begin in the second half of the year.

In over-the-counter products (OTC), revenue stood at KRW 34.8 billion, representing a 15.9% increase from KRW 30 billion in the same quarter last year. EZN 6, an antipyretic analgesic, saw a 55% growth YOY due to the COVID pandemic, while Urusa, a fatigue remedy, grew 10% YOY. EasyDerm, a wet dressing, also grew by 28% YOY, while the effort to increase its distribution through pharmacies is set to continue through the second half of the year as well. Health functional foods saw a 40% growth YOY, with the offline distribution channels for Senomega, a brand of products designed to improve blood circulation, is set to expand.

An official from Daewoong stated, "With the successful establishment of Fexuclue, the No. 34 domestically developed new drug, in the market and Nabota's strong performance in botulinum toxin market in US and Europe, an unprecedented KRW 300 billion in sales has been achieved", adding that "Since this outcome is attributable in large part to Fexuclue and Nabota, wholly developed by Daewoong, this sales result is especially meaningful to us. We will continue our endeavor to become a global pharmaceutical company with a competitive edge in diverse business areas".

Meanwhile, Daewoong continues to acquire additional treatable indications for Fexuclue and to introduce Nabota in the treatable indications market, while striving to obtain marketing approval for Enavogliflozin, the first SGLT-2 deterrent to be developed by a Korean pharmaceutical company, from the Ministry of Food and Drug Safety within the year, as well as working toward obtaining biomedical product approval in China for Nabota. Furthermore, clinical trials are currently underway for DWN12088, a potential drug candidate for pulmonary fibrosis designated for fast-track approval by the U.S. Food and Drug Administration last July. Daewoong is also running number of R&D programs to develop cell and genetic drugs, while continuing on with its efforts to secure new pipeline for stem cell drugs and to bring in technology platforms for drug preparations and formulations.

Photo - https://mma.prnewswire.com/media/1947342/graph_on_Daewoong_Pharmaceutical_2022_3Q_financial_result.jpg
Logo - https://mma.prnewswire.com/media/1676530/Daewoong_Pharmaceuticals_Logo.jpg

Modal title

Also from this source

Daewoong Pharmaceutical, a leading healthcare company in Korea, has launched its botulinum toxin product NABOTA in Saudi Arabia

Daewoong Pharmaceutical, a leading healthcare company in Korea, has launched its botulinum toxin product NABOTA in Saudi Arabia

Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee), a leading healthcare company in Korea, announced the official launch of its...

Daewoong Presents Enavogliflozin's Phase 3 Pooled Analysis Results at 84th ADA Conference

Daewoong Pharmaceutical (CEOs Chang-jae Lee and Seongsoo Park) announced that it will present the pooled analysis results of the Phase 3 clinical...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

Banking & Financial Services

Banking & Financial Services

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.